Search Results - "Arvis, Catherine Dubos"

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial by Herbst, Roy S, Prof, Baas, Paul, Prof, Kim, Dong-Wan, MD, Felip, Enriqueta, MD, Pérez-Gracia, José L, MD, Han, Ji-Youn, Prof, Molina, Julian, MD, Kim, Joo-Hang, Prof, Arvis, Catherine Dubos, MD, Ahn, Myung-Ju, Prof, Majem, Margarita, MD, Fidler, Mary J, MD, de Castro, Gilberto, MD, Garrido, Marcelo, MD, Lubiniecki, Gregory M, MD, Shentu, Yue, PhD, Im, Ellie, MD, Dolled-Filhart, Marisa, PhD, Garon, Edward B, MD

“…Summary Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for…”
Get full text

Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC by Lesueur, Paul, Escande, Alexandre, Thariat, Juliette, Vauléon, Enora, Monnet, Isabelle, Cortot, Alexis, Lerouge, Delphine, Danhier, Serge, Dô, Pascal, Dubos‐Arvis, Catherine, Chouaïd, Christos, Gervais, Radj

“…Introduction Randomized prospective studies on patients with metastatic non‐small‐cell lung cancers (NSCLCs) showed that anti‐programmed death‐1 (PD‐1) agents…”
Get full text

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial by Park, Keunchil, Prof, Tan, Eng-Huat, MD, O'Byrne, Ken, Prof, Zhang, Li, Prof, Boyer, Michael, Prof, Mok, Tony, Prof, Hirsh, Vera, Prof, Yang, James Chih-Hsin, Prof, Lee, Ki Hyeong, MD, Lu, Shun, Prof, Shi, Yuankai, MD, Kim, Sang-We, MD, Laskin, Janessa, MD, Kim, Dong-Wan, Prof, Arvis, Catherine Dubos, MD, Kölbeck, Karl, MD, Laurie, Scott A, MD, Tsai, Chun-Ming, Prof, Shahidi, Mehdi, MD, Kim, Miyoung, MD, Massey, Dan, PhD, Zazulina, Victoria, MD, Paz-Ares, Luis, MD

“…Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line…”
Get full text

Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO) by Wislez, Marie, Mazieres, Julien, Lavole, Armelle, Zalcman, Gérard, Carre, Olivier, Egenod, Thomas, Caliandro, Raffaele, Dubos-Arvis, Catherine, Jeannin, Gaelle, Molinier, Olivier, Massiani, Marie-Ange, Langlais, Alexandra, Morin, Franck, Le Pimpec Barthes, Francoise, Brouchet, Laurent, Assouad, Jalal, Milleron, Bernard, Damotte, Diane, Antoine, Martine, Westeel, Virginie

“…BackgroundThe IONESCO (IFCT-1601) trial assessed the feasibility of neoadjuvant durvalumab, for early-stage resectable non-small-cell lung cancer…”
Get full text

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression by Schuler, Martin, Tan, Eng-Huat, O’Byrne, Kenneth, Zhang, Li, Boyer, Michael, Mok, Tony, Hirsh, Vera, Yang, James Chih-Hsin, Lee, Ki Hyeong, Lu, Shun, Shi, Yuankai, Kim, Sang-We, Laskin, Janessa, Kim, Dong-Wan, Arvis, Catherine Dubos, Kölbeck, Karl, Massey, Dan, Märten, Angela, Paz-Ares, Luis, Park, Keunchil

“…Purpose In the randomized phase IIb LUX-Lung 7 trial, afatinib significantly improved progression-free survival (PFS) and time-to-treatment failure vs…”
Get full text

Assessment of multi-contaminant exposure in a cancer treatment center: a 2-year monitoring of molds, mycotoxins, endotoxins, and glucans in bioaerosols by Heutte, Natacha, André, Véronique, Dubos Arvis, Catherine, Bouchart, Valérie, Lemarié, Françoise, Legendre, Patrick, Votier, Edwige, Louis, Marie-Yolande, Madelaine, Stéphane, Séguin, Virginie, Gente, Stéphanie, Vérité, Philippe, Garon, David

“…Indoor air quality in health care facilities is a major public health concern, particularly for immunocompromised patients who may be exposed to…”
Get full text

Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1–Positive NSCLC by Baas, Paul, Garon, Edward B., Herbst, Roy S., Felip, Enriqueta, Perez-Gracia, Jose Luis, Han, Ji-Youn, Molina, Julian R., Kim, Joo-Hang, Dubos Arvis, Catherine, Ahn, Myung-Ju, Majem, Margarita, Fidler, Mary J., Barlesi, Fabrice, Castro, Gilberto, Garrido, Marcelo, Shentu, Yue, Lubiniecki, Gregory M., Im, Ellie, Kim, Dong-Wan

“…Abstract only…”
Get full text

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018 by Guisier, Florian, Dubos-Arvis, Catherine, Viñas, Florent, Doubre, Helene, Ricordel, Charles, Ropert, Stanislas, Janicot, Henri, Bernardi, Marie, Fournel, Pierre, Lamy, Régine, Pérol, Maurice, Dauba, Jerome, Gonzales, Gilles, Falchero, Lionel, Decroisette, Chantal, Assouline, Pascal, Chouaid, Christos, Bylicki, Olivier

“…Immune-checkpoint inhibitor (ICI) efficacy in patients with NSCLC harboring molecular alterations remains poorly elucidated. This study was undertaken to…”
Get more information

Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study by Herbst, Roy S, Garon, Edward B, Kim, Dong-Wan, Cho, Byoung Chul, Perez-Gracia, Jose L, Han, Ji-Youn, Arvis, Catherine Dubos, Majem, Margarita, Forster, Martin D, Monnet, Isabelle, Novello, Silvia, Szalai, Zsuzsanna, Gubens, Matthew A, Su, Wu-Chou, Ceresoli, Giovanni Luca, Samkari, Ayman, Jensen, Erin H, Lubiniecki, Gregory M, Baas, Paul

“…In the KEYNOTE-010 study, pembrolizumab improved overall survival (OS) versus docetaxel in previously treated, programmed death-ligand 1 (PD-L1)‒expressing…”
Get full text

Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients by Lasnon, Charline, Desmonts, Cédric, Quak, Elske, Gervais, Radj, Do, Pascal, Dubos-Arvis, Catherine, Aide, Nicolas

“…Purpose We prospectively evaluated whether a strategy using point spread function (PSF) reconstruction for both diagnostic and quantitative analysis in…”
Get full text

Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors by Saboundji, Karima, Auliac, Jean-Bernard, Pérol, Maurice, François, Géraldine, Janicot, Henri, Marcq, Marie, Dubos-Arvis, Catherine, Renault, Aldo, Guisier, Florian, Odier, Luc, Gervais, Radj, Chouaïd, Christos

“…Background The prognosis of patients with non-small cell lung cancer (NSCLC) who develop leptomeningeal metastasis (LM) is poor. Objective To assess the…”
Get full text

TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) by Guigay, Joel, Fayette, Jerome, Mesia, Ricard, Lafond, Cedrik, Saada-Bouzid, Esma, Geoffrois, Lionnel, Martin, Laurent, Cupissol, Didier, Capitain, Olivier, Castanie, Helene, Vansteene, Damien, Schafhausen, Philippe, Dubos Arvis, Catherine, Even, Caroline, Sire, Christian, Delhommeau, Melissa, Michel, Cecile, Bourhis, Jean, Keilholz, Ulrich, Auperin, Anne

“…Abstract only 6002 Background: After promising results from the GORTEC TPEx phase II trial, the role of taxane instead of 5FU in 1st-line R/M HNSCC…”
Get full text

Factors associated with better overall survival (OS) in patients with previously treated, PD-L1–expressing, advanced NSCLC: Multivariate analysis of KEYNOTE-010 by Herbst, Roy S., Baas, Paul, Kim, Dong-Wan, Felip, Enriqueta, Perez-Gracia, Jose Luis, Han, Ji-Youn, Molina, Julian R., Kim, Joo-Hang, Dubos Arvis, Catherine, Ahn, Myung-Ju, Majem, Margarita, Fidler, Mary J., Castro, Gilberto, Garrido, Marcelo, Ellison, Misoo C., Samkari, Ayman, Lubiniecki, Gregory M., Garon, Edward B.

“…Abstract only 9090 Background: We identified factors associated with better OS for previously treated, PD-L1–expressing advanced NSCLC using data from…”
Get full text

Off-Label Use of Crizotinib as a Neoadjuvant Treatment for a Young Patient When Conventional Chemotherapy Gave No Benefits in Stage IIIA Non-Small Cell Lung Cancer by Dumont, Delphine, Dô, Pascal, Lerouge, Delphine, Planchard, Gaëtane, Riffet, Marc, Dubos-Arvis, Catherine, Danhier, Serge, Gervais, Radj

“…BACKGROUND The treatment of locally advanced non-small cell lung cancer involves a combination of chemotherapy, surgery, and radiotherapy. Each case is…”
Get full text

Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study) by Auliac, Jean-Bernard, Monnet, Isabelle, Dubos-Arvis, Catherine, Chiappa, Anne Marie, Baize, Nathalie, Bota, Suzana, Vergnenegre, Alain, Doubre, Helene, Locher, Chrystele, Bizieux, Acya, Robinet, Gilles, Chouaid, Christos

“…Background Chromosomal translocations involving the anaplastic lymphoma kinase gene ( ALK ) are rare oncogenic events found in 3–5% of non-small-cell lung…”
Get full text

First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs) by Hirsh, Vera, Yang, James Chih-Hsin, Tan, Eng-Huat, O'Byrne, Ken, Zhang, Li, Boyer, Michael J., Mok, Tony, Lee, Ki Hyeong, Lu, Shun, Shi, Yuankai, Kim, Sang-We, Laskin, Janessa J., Kim, Dong-Wan, Dubos Arvis, Catherine, Kölbeck, Karl, Schuler, Martin H., Massey, Dan, Maerten, Angela, Paz-Ares, Luis, Park, Keunchil

“…Abstract only…”
Get full text

Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC by Herbst, Roy S., Baas, Paul, Perez-Gracia, Jose Luis, Felip, Enriqueta, Kim, Dong-Wan, Han, Ji-Youn, Molina, Julian R., Kim, Joo-Hang, Dubos Arvis, Catherine, Ahn, Myung-Ju, Majem, Margarita, Fidler, Mary J., Surmont, Veerle, Castro, Gilberto, Garrido, Marcelo, Shentu, Yue, Dolled-Filhart, Marisa, Im, Ellie, Garon, Edward B.

“…Abstract only…”
Get full text

Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010 by Garon, Edward B., Herbst, Roy S., Kim, Dong-Wan, Felip, Enriqueta, Perez-Gracia, Jose Luis, Han, Ji-Youn, Molina, Julian R., Kim, Joo-Hang, Dubos Arvis, Catherine, Ahn, Myung-Ju, Majem, Margarita, Fidler, Mary J., Gubens, Matthew A., Castro, Gilberto, Garrido, Marcelo, Shentu, Yue, Im, Ellie, Lubiniecki, Gregory M., Baas, Paul

“…Abstract only…”
Get full text

Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial by de Marinis, Filippo, Vergnenegre, Alain, Passaro, Antonio, Dubos-Arvis, Catherine, Carcereny, Enric, Drozdowskyj, Ana, Zeaiter, Ali, Perez-Moreno, Pablo, Rosell, Rafael

“…This analysis investigates incidence and time course of rash in the EURTAC study. Patients with EGFR mutation-positive non-small-cell lung cancer were…”
Get full text

Oxaliplatin-induced bronchiolitis obliterans organizing pneumonia following hyperthermic intraperitoneal chemotherapy by Le Baut, Guillaume, Guilloit, Jean-Marc, Leprince, Vincent, Ollivier, Yann, Dubos-Arvis, Catherine, Do, Pascal, Sutter, Jasmine, Loge, Ludovic, Gervais, Radj

“…Oxaliplatin given systemically is associated with pneumonitis in less than 1% of cases. This case report describes acute respiratory failure, due to…”
Get full text